Skip to main content
. 2026 Oct 29;17:1947706. doi: 10.3389/fpsyt.2026.1947706

Table 5.

Adverse effects according to treatment type.

Adverse effect Monotherapy, n (%) n = 365 Concomitant treatment, n (%) n = 285 Total, n (%) N = 650 p*
Any adverse effect 43 (11.8) 96 (33.7) 139 (21.4) <0.001
Sedation 14 (3.8) 62 (21.8) 76 (11.7) <0.001
Weight gain 9 (2.5) 54 (18.9) 63 (9.7) <0.001
Loss of appetite 9 (2.5) 3 (1.1) 12 (1.8) 0.184
Bruxism 8 (2.2) 1 (0.4) 9 (1.4) 0.085
Palpitations 5 (1.4) 2 (0.7) 7 (1.1) 0.475
Nausea 2 (0.5) 2 (0.7) 4 (0.6) 1.000
Sexual dysfunction 0 (0.0) 3 (1.1) 3 (0.5) 0.084
Akathisia 1 (0.3) 1 (0.4) 2 (0.3) 1.000
Hyperprolactinaemia 0 (0.0) 2 (0.7) 2 (0.3) 0.192
Headache 1 (0.3) 0 (0.0) 1 (0.2) 1.000
QTc prolongation 0 (0.0) 1 (0.4) 1 (0.2) 0.438
Vomiting 1 (0.3) 0 (0.0) 1 (0.2) 1.000
Dry mouth 1 (0.3) 0 (0.0) 1 (0.2) 1.000
Other 0 (0.0) 3 (1.1) 3 (0.5) 0.084

Adverse effects were counted among the 139 patients with a recorded adverse effect; a patient could have more than one adverse effect. Percentages use the group size shown in the column heading as denominator. *Pearson chi-square test, or Fisher’s exact test when an expected cell count was < 5.